Media Highlights and Announcements
November 04, 2021
In this article, the Financial Review shares some information on our accomplishments, IPO and overall progress towards our goals.
After closing our initial public offering (IPO), the Motley Fool shares details on Artrya’s AI technology and how it could disrupt the detection of coronary artery disease for years to come.
October 26, 2021
Amid a biotech boom, see how Artrya, an aussie medtech company, is pioneering the detection and assessment of the underlying cause of heart attack.
October 25, 2021
Artrya’s co-founder and Managing Director, John Barrington AM, recently took part in a Q&A with Stockhead.
Artrya has lodged a prospectus with ASIC with a view to list on the Australian Stock Exchange.
September 23, 2021
We’re proud to be acknowledged in Signify Research’s Product Developments & Technology Trends report.
Business NewsJune 21, 2021
Several exciting AI innovations are emerging from WA, and the world is watching.
University of Western AustraliaMay 31, 2021
AI to predict heart disease.
Australian Financial ReviewMay 25, 2021
Artrya raises $15m for AI software to transform cardiac imaging.
March 31, 2021
MTPConnect talks to Artrya. In this week’s episode, we chat with WA-based digital health company Artrya’s Co-Founders.